Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission. The Fukouka Bone Marrow Transplant Group.
Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission. The Fukouka Bone Marrow Transplant Group.
复制标题
粒细胞集落刺激因子联合骨髓清除化疗和自体血细胞移植治疗首次缓解期急性髓系白血病患者。
DOI：
10.1016/s0925-5710(97)00037-6
复制
发表时间：
1997
影响因子：
2.1
通讯作者：
Y. Niho
中科院分区：
文献类型：
--
作者：
M. Harada;K. Akashi;S. Hayashi;T. Eto;Y. Takamatsu;T. Teshima;Y. Hirota;S. Taniguchi;K. Nagafuji;S. Mizuno;H. Gondo;Y. Niho
我们进行了一项临床试验，以增加残留的白血病细胞的化疗敏感性，通过联合G-CSF骨髓消融化疗，包括阿糖胞苷（Ara-C），并促进自体血细胞移植（ABCT）治疗急性髓细胞白血病（AML）首次完全缓解。共16例患者连续接受粒细胞集落刺激因子（G-CSF）联合大剂量化疗（白消安，依托泊苷和阿糖胞苷），然后自体外周血祖细胞移植，已收集巩固化疗后。中位随访时间为44.5个月，5年无事件生存率为74.5%，仅3例白血病复发。这一初步观察结果表明，G-CSF联合预处理和ABCT作为AML缓解后治疗的有效性。
We conducted a clinical trial to increase the chemosensitivity of residual leukemic cells by combining G-CSF to marrow-ablative chemotherapy, including cytosine arabinoside (Ara-C), and facilitated by autologous blood cell transplantation (ABCT) for treatment of acute myelogenous leukemia (AML) in first complete remission. A total of 16 patients were consecutively treated with granulocyte colony-stimulating factor (G-CSF)-combined high-dose chemotherapy (busulfan, etoposide and Ara-C) followed by autotransplantation of peripheral blood progenitor cells, which had been collected after the consolidation chemotherapy. At a median follow-up time of 44.5 months, the probability of 5-year event-free survival was 74.5% with only three leukemic relapses. This preliminary observation suggests the effectiveness of G-CSF-combined conditioning and ABCT as a post-remission therapy for AML.